Catalog No.
RHD64403
Species reactivity
Human, Mouse
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, WB: 1:500-1:2000
Target
CCNE, G1/S-specific cyclin-E1, CCNE1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P24864
Applications
ELISA, FCM, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3G59
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
Pim1 is Critical in T-cell-independent B-cell Response and MAPK Activation in B Cells., PMID:39505064
POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY., PMID:39089269
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response., PMID:38992028
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group., PMID:38894867
Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric Cancer., PMID:38748981
Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer., PMID:38717153
The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression., PMID:38050871
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas., PMID:37820398
Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations., PMID:37656059
Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial., PMID:37325934
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers., PMID:37279095
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer., PMID:36930815
Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment., PMID:36916290
Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay., PMID:36866462
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors., PMID:33745032
RPL21 siRNA Blocks Proliferation in Pancreatic Cancer Cells by Inhibiting DNA Replication and Inducing G1 Arrest and Apoptosis., PMID:33014855
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer., PMID:31818495
Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection., PMID:31320595
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma., PMID:30538135
Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining., PMID:30268468
Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer., PMID:29433585
Transgelin mediates transforming growth factor-β1-induced proliferation of human periodontal ligament cells., PMID:28590058
Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer., PMID:27232515
The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer., PMID:25786580
Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes., PMID:25527175
EBV-LMP1-targeted DNAzyme induces DNA damage and causes cell cycle arrest in LMP1-positive nasopharyngeal carcinoma cells., PMID:24042231
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma., PMID:23775435
[Identification of HBx-related integration sites in HBsAg-positive hepatocellular carcinoma biopsy]., PMID:23044207
Depletion of SUMO ligase hMMS21 impairs G1 to S transition in MCF-7 breast cancer cells., PMID:22906975
Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1., PMID:21455311
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients., PMID:21321214
Role of caspases and CD95/Fas in the apoptotic effects of a nucleotide analog PMEG in CCRF-CEM cells., PMID:20683014
Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification., PMID:20530685
Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C., PMID:20530684
In CD28-costimulated human naïve CD4+ T cells, I-κB kinase controls the expression of cell cycle regulatory proteins via interleukin-2-independent mechanisms., PMID:20465575
An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells., PMID:19758748
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma., PMID:19454496
Aberrant expression of cyclin E in low-risk node negative breast cancer., PMID:18607847
Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival., PMID:18305181
Cyclin E1 knockdown induces apoptosis in cancer cells., PMID:16808878
For research use only. Not for human or drug use.
